{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T18:36:01Z","timestamp":1758393361417,"version":"3.37.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,8,8]],"date-time":"2020-08-08T00:00:00Z","timestamp":1596844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,8]],"date-time":"2020-08-08T00:00:00Z","timestamp":1596844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s11255-020-02584-x","type":"journal-article","created":{"date-parts":[[2020,8,8]],"date-time":"2020-08-08T09:02:52Z","timestamp":1596877372000},"page":"283-290","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Current treatment practices for anemia in patients with chronic kidney disease and future opportunities with hypoxia-inducible factor prolyl hydroxylase inhibitors: a narrative review"],"prefix":"10.1007","volume":"53","author":[{"given":"Mercedes","family":"Kile","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8327-4282","authenticated-orcid":false,"given":"Patcharaporn","family":"Sudchada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,8]]},"reference":[{"key":"2584_CR1","first-page":"271","volume":"2","author":"The Kidney Disease: Improving Global Outcomes (KDIGO)","year":"2012","unstructured":"The Kidney Disease: Improving Global Outcomes (KDIGO) (2012) KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2:271\u2013335","journal-title":"Kidney Int Suppl"},{"key":"2584_CR2","unstructured":"National Clinical Guideline Centre (2015) Anaemia management in chronic kidney disease: update 2015 NICE guideline 8. National Institute for Health and Care Excellence (NICE). https:\/\/www.nice.org.uk\/guidance\/ng8. Accessed 26 Sept 2019"},{"key":"2584_CR3","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1159\/000455166","volume":"45","author":"F Locatelli","year":"2017","unstructured":"Locatelli F, Fishbane S, Block GA, Macdougall IC (2017) Targeting hypoxia-inducible factors for the treatment of anemia in chronic kidney disease patients. Am J Nephrol 45:187\u2013199","journal-title":"Am J Nephrol"},{"key":"2584_CR4","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1097\/MNH.0000000000000317","volume":"26","author":"D Collister","year":"2017","unstructured":"Collister D, Rigatto C, Tangri N (2017) Anemia management in chronic kidney disease and dialysis: a narrative review. Curr Opin Nephrol Hypertens 26:214\u2013218","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2584_CR5","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1186\/s12882-017-0688-1","volume":"18","author":"A Mikhail","year":"2017","unstructured":"Mikhail A, Brown C, Williams JA et al (2017) Renal association clinical practice guideline on anaemia of chronic kidney disease. BMC Nephrol 18:345","journal-title":"BMC Nephrol"},{"key":"2584_CR6","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1053\/j.ajkd.2013.06.008","volume":"62","author":"AS Kliger","year":"2013","unstructured":"Kliger AS, Foley RN, Goldfarb DS et al (2013) KDOQI US Commentary on the 2012 KDIGO clinical practice guideline for anemia in CKD. Am J Kidney Dis 62:849\u2013859","journal-title":"Am J Kidney Dis"},{"key":"2584_CR7","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3389\/fmed.2017.00259","volume":"4","author":"W Li","year":"2019","unstructured":"Li W, Zhao Y, Fu P (2019) Hypoxia induced factor in chronic kidney disease: friend or foe? Front Med (Lausanne) 4:259","journal-title":"Front Med (Lausanne)"},{"key":"2584_CR8","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJMoa1813599","volume":"381","author":"N Chen","year":"2019","unstructured":"Chen N, Hao C, Peng X et al (2019) Roxadustat for anemia in patients with kidney disease not receiving dialysis. N Engl J Med 381:1001\u20131010","journal-title":"N Engl J Med"},{"key":"2584_CR9","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/1744-9987.12888","volume":"24","author":"T Akizawa","year":"2020","unstructured":"Akizawa T, Otsuka T, Reusch M, Ueno M (2020) Intermittent oral dosing of roxadustat in peritoneal dialysis chronic kidney disease patients with anemia: a randomized, phase 3, multicenter, open-label study. Ther Apher Dial 24:115\u2013125","journal-title":"Ther Apher Dial"},{"key":"2584_CR10","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1053\/j.ajkd.2016.12.011","volume":"69","author":"N Gupta","year":"2017","unstructured":"Gupta N, Wish JB (2017) Hypoxia-inducible factor prolyl hydroxylase inhibitors: a potential new treatment for anemia in patients with CKD. Am J Kidney Dis 69:815\u2013826","journal-title":"Am J Kidney Dis"},{"key":"2584_CR11","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMoa1901713","volume":"381","author":"N Chen","year":"2019","unstructured":"Chen N, Hao C, Liu BC et al (2019) Roxadustat treatment for anemia in patients undergoing long-term dialysis. N Engl J Med 381:1011\u20131022","journal-title":"N Engl J Med"},{"key":"2584_CR12","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2019060623","author":"T Akizawa","year":"2020","unstructured":"Akizawa T, Iwasaki M, Yamaguchi Y et al (2020) Phase 3, randomized, double-blind, active-comparator (darbepoetin alfa) study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan. JASN. https:\/\/doi.org\/10.1681\/ASN.2019060623","journal-title":"JASN"},{"key":"2584_CR13","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1093\/ndt\/gfy055","volume":"34","author":"VH Haase","year":"2019","unstructured":"Haase VH, Block GA, Pergola PE et al (2019) Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents. Nephrol Dial Transplant 34:90\u201399","journal-title":"Nephrol Dial Transplant"},{"key":"2584_CR14","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1159\/000499111","volume":"49","author":"T Akizawa","year":"2019","unstructured":"Akizawa T, Macdougall IC, Berns JS et al (2019) Long-term efficacy and safety of molidustat for anemia in chronic kidney disease: DIALOGUE extension studies. Am J Nephrol 49:271\u2013280","journal-title":"Am J Nephrol"},{"key":"2584_CR15","doi-asserted-by":"publisher","first-page":"28","DOI":"10.2215\/CJN.02510218","volume":"14","author":"IC Macdougall","year":"2019","unstructured":"Macdougall IC, Akizawa T, Berns JS, Bernhardt T, Krueger T (2019) Effects of molidustat in the treatment of anemia in CKD. Clin J Am Soc Nephrol 14:28\u201339","journal-title":"Clin J Am Soc Nephrol"},{"key":"2584_CR16","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1159\/000464476","volume":"45","author":"ER Martin","year":"2017","unstructured":"Martin ER, Smith MT, Maroni BJ et al (2017) Clinical trial of vadadustat in patients with anemia secondary to stage 3 or 4 chronic kidney disease. Am J Nephrol 45:380\u2013388","journal-title":"Am J Nephrol"},{"key":"2584_CR17","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1093\/ndt\/gfy055","volume":"34","author":"VH Haase","year":"2019","unstructured":"Haase VH, Chertow GM, Block GA et al (2019) Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents. Nephrol Dial Transpl 34:90\u201399","journal-title":"Nephrol Dial Transpl"},{"key":"2584_CR18","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1159\/000502012","volume":"143","author":"T Akizawa","year":"2019","unstructured":"Akizawa T, Macdougall IC, Berns JS et al (2019) Iron regulation by molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease. Nephron 143:243\u2013254","journal-title":"Nephron"},{"key":"2584_CR19","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1053\/j.ackd.2019.04.004","volume":"26","author":"NS Sanghani","year":"2019","unstructured":"Sanghani NS, Haase VH (2019) Hypoxia-inducible factor activators in renal anemia: current clinical experience. Adv Chronic Kidney Dis 26:253\u2013266","journal-title":"Adv Chronic Kidney Dis"},{"key":"2584_CR20","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1007\/s11255-018-1940-8","volume":"50","author":"D Xie","year":"2018","unstructured":"Xie D, Wang J, Wu X, Li M (2018) Effect of daprodustat on anemia in patients with chronic kidney disease: a meta-analysis. Int Urol Nephrol 50:2201\u20132206","journal-title":"Int Urol Nephrol"},{"key":"2584_CR21","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1681\/ASN.2014111139","volume":"27","author":"L Holdstock","year":"2016","unstructured":"Holdstock L, Meadowcroft AM, Maier R et al (2016) Four-week studies of oral hypoxia-inducible factor-prolyl hydroxylase inhibitor GSK1278863 for treatment of anemia. J Am Soc Nephrol 27:1234\u20131244","journal-title":"J Am Soc Nephrol"},{"key":"2584_CR22","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1053\/j.ajkd.2015.11.021","volume":"67","author":"RA Brigandi","year":"2016","unstructured":"Brigandi RA, Johnson B, Oei C et al (2016) A novel hypoxia-inducible factor-prolyl hydroxylase inhibitor (GSK1278863) for anemia in CKD: a 28-day, phase 2A randomized trial. Am J Kidney Di 67:861\u2013871","journal-title":"Am J Kidney Di"},{"key":"2584_CR23","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1159\/000454818","volume":"45","author":"T Akizawa","year":"2016","unstructured":"Akizawa T, Tsubakihara Y, Nangaku M et al (2016) Effects of daprodustat, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor on anemia management in Japanese hemodialysis sub-jects. Am J Nephrol 45:127\u2013135","journal-title":"Am J Nephrol"},{"key":"2584_CR24","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29. Identifier NCT01977482, Evaluation of dose response relationship, safety and efficacy of GSK1278863 in hemodialysis-dependent subjects with chronic kidney disease associated anemia; 2013 Nov 6; [about 3 screens]. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01977482. Accessed 23 June 2020"},{"key":"2584_CR25","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/ckj\/sfy014","volume":"12","author":"AM Meadowcroft","year":"2019","unstructured":"Meadowcroft AM, Cizman B, Holdstock L et al (2019) Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis. Clin Kidney J 12:129\u2013138","journal-title":"Clin Kidney J"},{"key":"2584_CR26","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1186\/s12882-019-1547-z","volume":"20","author":"CK Bailey","year":"2019","unstructured":"Bailey CK, Caltabiano S, Cobitz AR et al (2019) A randomized, 29-day, dose-ranging, efficacy and safety study of daprodustat, administered three times weekly inpatients with anemia on hemodialysis. BMC Nephrol 20:372","journal-title":"BMC Nephrol"},{"key":"2584_CR27","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/ckj\/sfy013","volume":"12","author":"L Holdstock","year":"2019","unstructured":"Holdstock L, Cizman B, Meadowcroft AM et al (2019) Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease. Clin Kidney J. 12:129\u2013138","journal-title":"Clin Kidney J."},{"key":"2584_CR28","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s40262-017-0551-3","volume":"57","author":"KA Kansagra","year":"2018","unstructured":"Kansagra KA, Parmar D, Jani RH et al (2018) Phase I clinically study of ZYAN1, a novel prolyl-hydroxylase (PHD) inhibitor to evaluate the safety, tolerability, and pharmacokinetics following oral administration in healthy volunteers. Clin Pharmacokinet 57:87\u2013102","journal-title":"Clin Pharmacokinet"},{"key":"2584_CR29","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/1744-9987.12962","volume":"24","author":"Y Tsubakihara","year":"2020","unstructured":"Tsubakihara Y, Akizawa T, Nangaku M et al (2020) A 24-week anemia correction study of daprodustat in Japanese dialysis patients. Ther Apher Dial 24:108\u2013114","journal-title":"Ther Apher Dial"},{"key":"2584_CR30","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1159\/000500232","volume":"49","author":"DV Parmar","year":"2019","unstructured":"Parmar DV, Kansagra KA, Patel JC et al (2019) Outcomes of desidustat treatment in people with anemia and chronic kidney disease: a phase 2 study. Am J Nephrol 49:470\u2013478","journal-title":"Am J Nephrol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-020-02584-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-020-02584-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-020-02584-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,7]],"date-time":"2021-08-07T23:29:10Z","timestamp":1628378950000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-020-02584-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,8]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["2584"],"URL":"https:\/\/doi.org\/10.1007\/s11255-020-02584-x","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"type":"print","value":"0301-1623"},{"type":"electronic","value":"1573-2584"}],"subject":[],"published":{"date-parts":[[2020,8,8]]},"assertion":[{"value":"24 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors (PS and MK) declare that they have no potential conflict of interest regarding the publication of the paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}